Patents by Inventor Richard Jove

Richard Jove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200283421
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 10, 2020
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Publication number: 20200247750
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Application
    Filed: October 7, 2019
    Publication date: August 6, 2020
    Inventors: Sangkil NAM, Richard JOVE, Leandros SKALTSOUNIS
  • Publication number: 20200032255
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 30, 2020
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Patent number: 10435367
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 8, 2019
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • Patent number: 10253318
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 9, 2019
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Patent number: 10246471
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 2, 2019
    Assignees: City of Hope, The Regents of the University of California
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Publication number: 20180170915
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Publication number: 20180155367
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: October 27, 2017
    Publication date: June 7, 2018
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Patent number: 9856273
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 2, 2018
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Patent number: 9828342
    Abstract: One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 28, 2017
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David A. Horne, Richard Jove, Christopher Lincoln, Sangkil Nam, Larry Overman, Jun Xie
  • Patent number: 9688982
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 27, 2017
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Publication number: 20170037058
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 9, 2017
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Home, Richard Jove, Jun Xie, Claudia Kowolik
  • Patent number: 9527868
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 27, 2016
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Patent number: 9512076
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). One aspect of the invention relates to a method of treating CML using at least one indirubin derivative compound or a pharmaceutical composition thereof. Indirubin derivatives (IRDs) potently inhibited Signal Transducer and Activator of Transcription 5 (Stat5) protein in CML cells. Compound IRD 810 inhibits Bcr-Abl/Stat5 or Src/Stat5 signaling in human KCL-22 CML and imatinib-resistant human KCL-22 CML cells expressing the T315I mutant Bcr-Abl. Previous studies indicate that SFKs cooperate with Bcr-Abl to activate downstream Stat5 signaling. Activation of Stat5 was strongly blocked by IRD 810 in CML cells. IRDs disclosed herein have been identified as potent inhibitors of Bcr-Abl/Stat5 or SFK/Stat5 signaling pathway.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: December 6, 2016
    Assignee: CITY OF HOPE
    Inventors: Richard Jove, Sangkil Nam, Alexios-Leandros Skaltsounis
  • Patent number: 9345682
    Abstract: Signal Transducer and Activator of Transcription (STAT) proteins have a fundamental role cell signaling, and are activated by a large number of cytokines and growth factors. One member of the STAT family, STAT3, has a critical role in oncogenesis. The present invention relates generally to disruption of the pathway of STAT3 signaling in the treatment of human cancer. STAT3 activation is shown to be present in diverse tumor cell lines and tumors, to promote oncogenesis, to inhibit apoptosis, and to reduce sensitivity to chemotherapeutic agents. Inhibition of STAT3 signaling induces apoptosis specifically in tumor cell lines, and increases sensitivity to chemotherapeutic agents. The invention relates more particularly to methods, compositions, means of administering such compositions, and means for identifying such compositions for the inhibition of STAT3 intracellular signaling in the treatment of human cancers.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: May 24, 2016
    Assignees: University of South Florida, Yale University
    Inventors: Richard Jove, William Dalton, Said Sebti, Hua Yu, Richard Heller, Mark Jaroszeski, Richard A. Gilbert, Andrew D. Hamilton
  • Publication number: 20160068517
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Patent number: 9233976
    Abstract: The invention provides novel berbamine derivatives, and compositions or pharmaceutical compositions thereof. These berbamine derivatives have shown higher potency in killing cancer/tumor cells comparing to berbamine, and can be used in cancer/tumor treatments.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: January 12, 2016
    Assignee: CITY OF HOPE
    Inventors: David Horne, Jun Xie, Angela L. Perkins Harki, Richard Jove, Sangkil Nam, Wendong Huang, Rongzhen Xu
  • Patent number: 9200279
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: December 1, 2015
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Patent number: 9200280
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: December 1, 2015
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Publication number: 20150291622
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: April 17, 2015
    Publication date: October 15, 2015
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik